Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume 10, Issue 3, Pages 155-162Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-010-0101-7
Keywords
Vernal keratoconjunctivitis; Giant papillae; Mast cells stabilizer; Selective antihistamine; Dual-action drugs; Corticosteroids; Cyclosporine
Categories
Ask authors/readers for more resources
Vernal keratoconjunctivitis (VKC), an allergic inflammation of the conjunctiva affecting mainly children and adolescents, is categorized under the rubric of allergic conjunctivitis. Lack of uniform diagnostic and predefined staging criteria has been a bottleneck in formulating fixed guidelines to treat VKC. This lack of consensus among clinicians/researchers regarding diagnostic and grading standards has prevented us from making comparisons between the outcomes of different studies. To treat VKC, selection of a drug from many available options should be based on the duration and frequency of symptoms, grade and inflammation of giant papillae, and severity of corneal involvement. Consideration also should be given to the patient's specific needs. The basic tenet of treatment is optimal control of symptoms with a minimum of toxic side effects resulting from prolonged use of medication.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available